Ekf Diagnostics Share Discussion Threads

[kestelmill] 06/7/2017 16:48

Don't want to rain on your parade Wan - things are on the up - but isn't this the same management team who bought Selah Genomics for USD 35.6M plus milestone payments then less than two years later gave it back to Selah for nothing and wrote down GBP 41M off EKF's balance sheet?

[interstellar] 06/7/2017 15:55

It has taken a long time but finally things are moving in the right direction. Well done. Let's just hope that the cash being generated doen't burn a hole in the management's pockets so that are tempted to make another disastrous (American) acquisition.

[wan] 06/7/2017 09:13

It is likely that the investments in consumable capacity expansion in Germany and replacement of equipment in the US (mentioned in 2016), are starting to be felt. One assumes then that these investments, apart from targeting possible costs savings/increased margins, were in light of increased orders and will also support tenders for new contracts.

I note that in 2016 EKF had a particularly strong 3rd quarter (July - Sept), so hopefully the momentum currently being experienced continues and obviously even better if it accelerates!

[9degrees] 08/6/2017 17:57

odd 1 million shares just slipped through LATE TRADE AT 21.5P

[wan] 11/5/2017 11:27

Having just read EKF's AR, some ingredients look set to further improve the financials in 2017. This has now been borne out by the most recent trading update for the first quarter where it was good to see that the Board remain optimistic about the Company's prospects for the full year.

The impressive and growing installed base of POC instruments provides for an excellent recurring revenue model(razor/razor-blade model). Given the stable and predictable revenues from such a business model, and given plans to spin-off the Lab Diagnostics business (which will create value) along with a potential share buy back, does this imply that EKF might be looking at becoming a high paying dividend stock in the not too distant future? Or will the pure focus on POC diagnostics put EKF back in play as a take-over target (at a much higher premium than previous bids)?

Either way, the future appears to look very promising!

[intrinsicinvestor] 02/5/2017 12:45

And linked to previous CFD announcement presumably

[intrinsicinvestor] 02/5/2017 12:28

Interesting 8m+ deal today at 21.5..

[oilplays] 20/4/2017 16:27

Lots of buys today; anyone speculate?

[kestelmill] 24/3/2017 11:33

Hi All, I'm out of this one. Never thought a year ago I would be able to get out at north of 21p so absolutely delighted. Somehow made £3.5K on this share but on the whole it's not been an enjoyable journey and I have learned a lesson or two. So long and good luck!

KM

[wan] 20/3/2017 08:35

Square1...it will be interesting to see what the US open makes of the news (as I believe eyes from over there must be watching, especially given EKF's installed base of instruments).

Depending on how long things take and of course if it happens, in a low interest environment and in percentage terms, today's price and the buy back price offers of a potentially reasonable yield of circa 12%, especially so if things happen in quick fashion!

[square1] 20/3/2017 08:17

wan- they have clearly put themselves up for sale with offers above 21.5p IMO

[wan] 20/3/2017 07:50

I appreciate the directors currently hold a strong hand, but could today's news (and much improved Results) also provide the potential for a bid to emerge that values the company more in line with the value inflection and opportunity as that envisaged by splitting the company?

[silverfern] 20/3/2017 07:23

LOoks like end game . Company will leave AIM - expect PLUS market at best. AT least you can now get out at 21.5p. If I held I'd take that and not look back

[wan] 14/2/2017 08:48

7th Feb 2017
EKF's new Procalcitonin (PCT) study shows that testing reduces hospital costs and length of stay.

Sepsis carries a huge economic and human cost affecting over 27,000,000 people per year, and resulting in over 8,000,000 deaths per year 2. The USA spend over $20 billion dollars per year on sepsis care, so finding a way to screen and treat patients in the fastest, safest and most cost effective way is right at the top of many hospital agendas.

The EKF Diagnostics Procalcitonin LiquiColor® Test is a marker for bacterial infection and sepsis and can be used as a quick ten minute test, in conjunction with other tests, to quickly assess initial severity of sepsis. The test is CE marked and currently going through the FDA approval process. It is an open-channel test that can provide a cost effective solution for many hospital labs.
Full release -

[intrinsicinvestor] 08/2/2017 09:55

Well it looked like a very large 'cross' yesterday. (12m+)The amount on the buy side seems to equate to an amount that should be disclosed, so let's see. The price was below the then market too.

[wan] 07/2/2017 18:12

For the last couple of weeks there has been some relatively large individual trades reported (2m, 5m, 6m, 7m, 8m and 13m etc) all at the same price, so accordingly I would expect to see some holding announcements. If the Chairman has picked any of them up it could get quite interesting!

[interstellar] 09/1/2017 09:03

Some congratulations are in order. A good update

[stupidboypike] 09/1/2017 08:11

Does anyone have access to a recent brokers note on EKF? would appreciate a look.

Best regards SBP

[wan] 09/1/2017 07:25

Quite some turnaround at EKF, which looks set to continue with the current management making it happen!

[sirshagalot] 24/11/2016 14:35

Due for another tick up soon according to charts

[hamidahamida] 07/11/2016 23:10

Hi butchdogg nice to see you here, great company on the mend Flx is breaking out

[butchdogg] 07/11/2016 17:49

this just popped up on a scan.. looks interesting. Hi Hamid i see you over on the FLX thread too.